Organization (Industry)
bioMérieux (France)
ClinicalTrials.gov lists bioMérieux (France) as lead sponsor of 16 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 6 in 2026 and about 4 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo BiióMérieux S.A., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers bioMérieux (France): 16 lead-sponsored trials and 8 legal-entity registrations. Part of INSTITUT MERIEUX.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (59)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Inflammation | 16 |
| Sepsis | 15 |
| Disease | 6 |
| Cross Infection | 5 |
| Shock, Septic | 5 |
Showing 5 of 59 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 9 |
| 2022 | 7 |
| 2021 | 4 |
| 2020 | 6 |
| 2019 | 8 |
| 2018 | 4 |
| 2017 | 3 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 63% hit target (n=8) | 22% on time (n=9) |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 5 |
FDA recalls (54)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| MYLA Versions: 4.7, 4.7.1, 4.8, 4.8.1 and 4.8.2, part of the VIRTUO System | Class II | 2021-09-02 |
| MYLA software. Used to manage microbiology test workflow from the reception of requests to the transmission of results by transferring, storing, and displaying medical device data. | Class II | 2021-06-22 |
| NucliSENS¿ Magnetic Extraction Reagents | Class II | 2018-09-17 |
| VIDAS FSH, Ref 30407-01, IVD, Rx. The firm name on the label is bioMerieux SA, France. For use on the instruments of the VIDAS family (VITEK ImmunoDiagnostic Assay System) as an automated quantitative enzyme-linked fluorescent immunoassay (ELFA) for the determination of human follicle stimulating hormone (FSH) concentration in human serum or plasma (heparin). It is intended for use as an aid in the diagnosis of pituitary gland and gonadal disorders. | Class II | 2018-04-09 |
| The VITEK 2 Gram-Positive identification card (GP) is intended for use with the VITEK 2 Systems for the automated identification of most significant Gram-positive organisms. The VITEK 2 GP identification card Is a single-use disposable. GP TEST KIT VTK2 20 CARTES A microorganism differentiation and identification device is a device intended for medical purposes that consists of one or more components, such as differential culture media, biochemical reagents, and paper discs or paper strips impregnated with test reagents, that are usually contained in individual compartments and used to differentiate and identify selected microorganisms. | Class II | 2018-03-23 |
Showing 5 of 54 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 2 | 2023-07-17 |
Manufacturing and distribution sites (4)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| BIOMERIEUX SA | LA BALME LES GROTTES Isere, FR | FDA | |
| BIOMERIEUX SA | MARCY L ETOILE Rhone, FR | FDA | |
| BIOMERIEUX SA | Combourg Ille-et-Vilaine, FR | FDA | |
| BioMerieux SA | VERNIOLLE Ariege, FR | FDA |
Biomarker capability evidence (55)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BAMBI | Trial collaborator | Named in trial inclusion criteria |
| BAMBI | Trial collaborator | Named in trial inclusion criteria |
| CC2D1A | Trial collaborator | Named in trial inclusion criteria |
| IGFBP7 | Trial collaborator | Named in trial inclusion criteria |
| MVD | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 55 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under Institut Mérieux (France): journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.